Opioid Medications Halve Mortality but Reach Only a Quarter of Patients

Opioid use disorder remains a dominant public health crisis, affecting an estimated 3.7% of US adults (9,367,000 individuals) in 2022 and causing 53,774 deaths in 2024 [1]. While opioid agonist therapies like methadone and buprenorphine are highly effective at reducing both all-cause and overdose mortality, patients face a particularly high risk of death immediately after treatment cessation [2]. To combat this, acute care settings have increasingly focused on initiating medications for opioid use disorder directly in the emergency department, a strategy shown to significantly improve short-term treatment engagement compared to brief interventions alone [3, 4]. Despite these proven interventions, systemic barriers and fragmented care models continue to limit patient access to sustained pharmacological support, with only 25.1% of affected individuals in the US receiving these life-saving medications in 2022. A newly published clinical review synthesizes the latest evidence on optimizing medications for opioid use disorder, withdrawal management, and overdose reversal to help clinicians close this critical treatment gap.